SI
PTCT icon

Sofinnova Investments’s PTC Therapeutics PTCT Stock Holding History

Sofinnova Investments’s Portfolio PTCT Stock Details PTCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2020
Q3 		– Sell
-60,000
Closed -$3.04M – 83
2020
Q2 		$3.04M Buy
60,000
+10,000
+20% +$491K 0.19% 62
2020
Q1 		$2.23M Buy
+50,000
New +$2.52M 0.21% 51

Other funds holding PTCT

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
RI
RTW Investments New York $10B AUM 135.35% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
D.E. Shaw & Co
D.E. Shaw & Co New York $166B AUM 43.98% 1-Year Est. Return

Sofinnova Investments's PTCT Position: Q4 2025 in Review

Sofinnova Investments sold out of PTC Therapeutics (PTCT) in Q4 2025, closing a stake of 186,932 shares — an estimated $11.5M sold.

Sofinnova Investments first reported a position in PTCT in Q1 2018 and held it in 19 quarters. The position peaked at $29.5M in Q1 2025. 351 funds tracked by Wall St. Rank hold PTCT as of Q4 2025.

  • Sofinnova Investments reported no remaining PTC Therapeutics position as of Q4 2025 after selling out during the quarter.
  • Sofinnova Investments sold 186,932 PTC Therapeutics shares in Q4 2025, an estimated $11.5M.
  • Sofinnova Investments first reported a position in PTC Therapeutics in Q1 2018 and held it in 19 quarters.
  • Sofinnova Investments's PTC Therapeutics position peaked at $29.5M in Q1 2025.
  • 351 funds tracked by Wall St. Rank held PTC Therapeutics as of Q4 2025.

Based on Sofinnova Investments's 13F filing for Q4 2025, filed 13 Feb 2026.